PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.260
-0.060 (-4.55%)
Apr 25, 2025, 4:00 PM EDT - Market closed
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,567,099
Market Cap
57.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 2 days ago - PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 10 days ago - PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - GlobeNewsWire
- 18 days ago - PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 4 weeks ago - PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 4 weeks ago - PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - GlobeNewsWire
- 5 weeks ago - PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - GlobeNewsWire